Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02608528 · ClinicalTrials.gov registry record
Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- 10
- Enrollment target
NCT02608528: Clinical Trial study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02608528 is a clinical trial that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02608528 was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overall survival.
Interventions
- RADIATION [18F]fluoroglucose(FDG)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-10-22 |
| Est. Completion | 2019-07-18 |
Why NCT02608528 stopped before completion
NCT02608528 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which [18F]fluoroglucose(FDG) is the first listed.
NCT02608528 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02608528 about?
NCT02608528 is a clinical study titled "Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy". Evaluation of FDG PET/CT to image immunotherapy response in adult thoracic cancer. Compare pre- and post-treatment primary tumor uptake for FDG-PET/CT and correlate with clinical markers of response. PET/CT tumor metabolic response will also be correlated will to progression-free survival and overa...
What is the current status of trial NCT02608528?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2015-10-22. Estimated completion is 2019-07-18.
What interventions are being tested in trial NCT02608528?
The interventions under investigation include: [18F]fluoroglucose(FDG) (RADIATION).
Who is sponsoring clinical trial NCT02608528?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI